NCT07166744View on ClinicalTrials.gov

Contribution of Pathological Alpha-synuclein as a Diagnostic Biomarker for Dementia With Lewy Bodies

NANot yet recruitingINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

January 1, 2032

Study Completion Date

January 1, 2032

Conditions
Dementia With Lewy Bodies (DLB)Alzheimer's Disease (AD)
Interventions
OTHER

Biological : blood sampling

will be collected from the patient

OTHER

nasopharyngeal swab

will be collected from the patient

OTHER

Procedure : Lumbar puncture

will be collected from the patient

OTHER

Behavioral : clinical, functional, cognitive and psychiatric evaluations

will be collected from the patient

OTHER

MRI

will be done on the patient

All Listed Sponsors
lead

University Hospital, Strasbourg, France

OTHER

NCT07166744 - Contribution of Pathological Alpha-synuclein as a Diagnostic Biomarker for Dementia With Lewy Bodies | Biotech Hunter | Biotech Hunter